Catalent (NYSE:CTLT – Get Rating) had its target price lowered by Barclays from $62.00 to $58.00 in a report released on Tuesday, The Fly reports. The brokerage currently has an "overweight" rating on the stock. Barclays's price target would suggest a potential upside of 15.63% from the company's previous close.

Other research analysts have also issued reports about the stock. Argus lowered shares of Catalent from a "buy" rating to a "hold" rating in a research note on Monday, November 7th. Robert W. Baird decreased their price objective on shares of Catalent from $123.00 to $75.00 in a report on Wednesday, November 2nd. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a report on Friday, October 28th. Morgan Stanley decreased their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating on the stock in a report on Thursday, November 3rd. Finally, KeyCorp decreased their price objective on shares of Catalent from $125.00 to $85.00 and set an "overweight" rating on the stock in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $92.40.

Catalent Trading Up 1.2 %

Shares of Catalent stock opened at $50.16 on Tuesday. Catalent has a 52-week low of $40.69 and a 52-week high of $115.33. The company has a quick ratio of 2.08, a current ratio of 2.86 and a debt-to-equity ratio of 0.87. The company's 50-day simple moving average is $46.33 and its 200-day simple moving average is $71.89. The firm has a market cap of $9.03 billion, a price-to-earnings ratio of 21.44, a price-to-earnings-growth ratio of 3.63 and a beta of 1.24.

Insider Buying and Selling at Catalent

In related news, insider Manja Boerman sold 780 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Manja Boerman sold 780 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Grippo sold 2,451 shares of the company's stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $65.83, for a total transaction of $161,349.33. Following the transaction, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The disclosure for this sale can be found here. Insiders have sold 3,874 shares of company stock valued at $233,414 over the last quarter. Corporate insiders own 0.58% of the company's stock.

Hedge Funds Weigh In On Catalent

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bellevue Group AG acquired a new position in Catalent during the third quarter worth approximately $34,000. CX Institutional acquired a new position in Catalent during the second quarter worth approximately $37,000. Clear Street Markets LLC increased its position in Catalent by 408.1% during the second quarter. Clear Street Markets LLC now owns 376 shares of the company's stock worth $40,000 after purchasing an additional 302 shares during the last quarter. Motco acquired a new position in Catalent during the third quarter worth approximately $41,000. Finally, Alta Advisers Ltd acquired a new position in Catalent during the third quarter worth approximately $43,000. Institutional investors and hedge funds own 99.38% of the company's stock.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also

• Get a free copy of the StockNews.com research report on Catalent (CTLT)
• AMD Is Still One Of The Best Semiconductor Stocks Out There
• Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
• Is The Bottom In For Cyber-Security Stocks?
• Union Pacific, Norfolk Southern Pull into Buying Zone
• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.